Covid-19 Vaccine Responsiveness in MM and Waldenstrom (NCT04830046) | Clinical Trial Compass
CompletedNot Applicable
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
United States146 participantsStarted 2021-04-15
Plain-language summary
This research is being done to see if the immune (defense) system of people with Multiple Myeloma and Waldenstrom's Macroglobulinemia reacts to the COVID-19 vaccine.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age \>18 years.
* Lack of a contra-indication to a currently available COVID-19 vaccine.
* Diagnosis of MM according to International Myeloma Working Group (IWMG) criteria (Cohort 1) or Diagnosis of WM according to WHO criteria (Cohort 2)
* For treatment naïve WM patients (Cohort 2A):
* Patient must have no prior history of anticancer treatment for WM.
* The treating investigator must have no intention to initiate WM therapy within 2 months
* For WM patients receiving BTK inhibitor (Cohort 2B):
* Patient must have no history of cytotoxic chemotherapy within 1 year, and no history of other anticancer therapy within 6 months.
* For currently or previously treated WM patients (Cohort 2C):
* Patient must not be currently taking a BTK inhibitor or had recent exposure within 1 month of enrollment. Current or prior history of any other WM-directed therapy is allowed.
Exclusion Criteria:
\-